Kristen N Ganjoo

Publications

• The Treatment Outcome for Adult Patients with Ewing's Sarcoma. Ganjoo KN, Patel S. Curr Oncol Rep. 2013
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Advani RH, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K. Leuk Lymphoma. 2012; 53 (4): 718-20
• Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Cancer Invest. 2012; 30 (3): 231-5
• Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN. Clin Cancer Res. 2012; 18 (5): 1395-403
• Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. J Natl Compr Canc Netw. 2012; 10 (8): 951-60
• A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP. Oncology. 2011; 80 (1-2): 50-6
• Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Ganjoo KN, Patel S. Drugs. 2011; 71 (3): 321-30
• R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. J Clin Oncol. 2011; 29 (34): 4541-7
• 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. Mol Imaging Biol. 2010; 12 (2): 198-203
• A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. J Thorac Oncol. 2010; 5 (11): 1821-5
• Antiangiogenesis agents in the treatment of soft tissue sarcomas. Ganjoo K, Jacobs C. Cancer. 2010; 116 (5): 1177-83
• Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Cancer. 2010; 116 (1): 106-14
• NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. J Natl Compr Canc Netw. 2010: 8 Suppl 2 S1-41; quiz S42-4
• New developments in targeted therapy for soft tissue sarcoma. Ganjoo KN, Curr Oncol Rep. 2010; 12 (4): 261-5
• Soft tissue sarcoma. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. J Natl Compr Canc Netw. 2010; 8 (6): 630-74
• The Predictive Value of Tumor associated macrophages in leiomyosarcoma. Kristen Ganjoo, D Witten, M Patel, I Espinosa, T La, M van de Rijn, C Jacobs, R West. Am J of Clin Oncology. 2010
• Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Ganjoo KN, Demetri GD, Jacobs C, Patel S. Leuk Lymphoma. 2009; 50 (11): 1882-4
• Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Brar R, West R, Witten D, Raman B, Jacobs C, Ganjoo K. Case Rep Oncol. 2009; 2 (3): 242-250
• Breast angiosarcomas: Case series and expression of vascular endothelial growth factor Rondeep Brar, Robert West, Daniela Witten, Bhargav Raman, Charlotte Jacobs, Kristen Ganjoo. Case Reports in Oncology. 2009: 2 242-50
• Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Espinosa I, Beck AH, Lee CH, Zhu S, Montgomery KD, Marinelli RJ, Ganjoo KN, Nielsen TO, Gilks CB, West RB, van de Rijn M. Am J Pathol. 2009; 174 (6): 2347-56
• Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy. Ganjoo KN, Raman R, Sobel RA, Pinto HA. Leuk Lymphoma. 2009; 50 (4): 673-5
• Trabectedin: an anticancer drug from the sea. Ganjoo KN, Patel SR. Expert Opin Pharmacother. 2009; 10 (16): 2735-43
• Review of erlotinib in the treatement of advanced non-small cell lung cancer Kristen N Ganjoo, Heather Wakelee. Biologics; Targets & Therapy. 2008
• The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. J Cancer Res Clin Oncol. 2008; 134 (3): 381-7
• Antiangiogenesis: a new approach to the treatment of lymphoma. Ganjoo K, Leuk Lymphoma. 2007; 48 (3): 454-5
• Non-Hodgkin lymphoma of the breast. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S. Cancer. 2007; 110 (1): 25-30
• Review of erlotinib in the treatment of advanced non-small cell lung cancer. Ganjoo KN, Wakelee H. Biologics. 2007; 1 (4): 335-46
• Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Cancer. 2006; 106 (10): 2158-64
• Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ. Leuk Lymphoma. 2006; 47 (6): 998-1005
• A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD. Am J Clin Oncol. 2005; 28 (2): 169-72
• Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C, Loehrer PJ. Oncology. 2003; 65 (3): 218-23
• Unusual locations of involvement by malignancies: Case 1. Testicular plasmacytoma. Shafqat A, Yum MN, Abanour R, Ganjoo KN. J Clin Oncol. 2003; 21 (17): 3368-9
• A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study. Ganjoo KN, Gordon MS, Sandler AB, Warner RE, Fife K, Poirier S, Seshadri R, Loehrer PJ. Oncology. 2002; 62 (4): 299-304
• Germ cell tumor associated primitive neuroectodermal tumors. Ganjoo KN, Foster RS, Michael H, Donohue JP, Einhorn LH. J Urol. 2001; 165 (5): 1514-6
• Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Ganjoo KN, Rieger KM, Kesler KA, Sharma M, Heilman DK, Einhorn LH. Cancer. 2000; 88 (5): 1051-6
• Lung cancer presenting with solitary bone metastases. Case 1: metastatic adenocarcinoma to the patella. Ganjoo KN, Loyal JA, Cramer HM, Loehrer PJ. J Clin Oncol. 1999; 17 (9): 2995-7
• Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. J Clin Oncol. 1999; 17 (11): 3457-60
• Primary mediastinal nonseminomatous germ cell tumors: the influence of postchemotherapy pathology on long-term survival after surgery. Kesler KA, Rieger KM, Ganjoo KN, Sharma M, Fineberg NS, Einhorn LH, Brown JW. J Thorac Cardiovasc Surg. 1999; 118 (4): 692-700